Lumito (LUMITO) Q3 2026 earnings summary

Executive summary

• First commercial order outside the Nordic region, worth ~€4,000, included SCIZYS Erbium kits and Scan-as-a-Service; 9M sales reached SEK 116k.

• Commercial focus shifts to converting customer interest and evaluations into paid projects, expanding CRO channels and growing recurring revenue from consumables and analysis services.

Financial highlights

• Q3 net sales were SEK 38k (0); operating loss was SEK 7.921m (SEK 8.873m) and net loss SEK 8.073m (SEK 9.511m).

• 9M net sales were SEK 116k (0); operating loss was SEK 27.906m (SEK 31.074m) and net loss SEK 28.627m (SEK 32.589m).

• 9M external and personnel costs fell by SEK 2.534m YoY following cost-efficiency measures.

• Q3 operating cash flow after working-capital changes was -SEK 252k (-SEK 2.967m); 9M was -SEK 11.143m (-SEK 17.124m).

Outlook and guidance

• Strategic priorities are converting customer discussions and evaluations into paid projects, scaling CRO and strategic partner channels, and building recurring consumables and service revenue.

• Management assessed working capital as secured into the later part of Q1 2027; this outlook partly depends on exercise of TO10 warrants in January 2027.

• Around 20 qualified discussions were initiated at the European Congress of Pathology; follow-up aims to develop promising leads into pilots, partnerships and commercial agreements.